"We are a very large lab with a Regional Genetics Service serving a population of nearly 6 million people, and the Cartagenia BENCH lab product is the perfect tool for us to add quality and consistency to our data collection and analytical needs," said Dom McMullan, Principal Clinical Scientist at WMRGL. "BENCH lab is an attractive option because it's platform neutral, with very robust and adaptable filtering options, allowing us to more easily manage, collect and store various types of microarray data. BENCH lab will provide us a more consistent output and aid us in bringing consistency to our analyses."
Cartagenia CEO Herman Verrelst noted that working with BWHFT and WMRGL provides Cartagenia an important entrance to the UK market as well as the UK EACH research project.
"We are very pleased to have our BENCH
lab tool serving such a respected and important lab as the WMRGL," Verrelst said. "We believe partnering with WMRGL in the piloting of a national UK-based CNV database will prove that our BENCH
lab platform is the perfect collaborative tool that allows labs to pool and share information and improve the quality of the data and diagnostic yield of their efforts. Furthermore, this database could serve as a cornerstone in our effort to market to other genetics labs in the UK and in
Europe as well as help create a network to provide and promote better patient care."
About BWHFT and WMRGL
BWHFT provides a range of healthcare services to women and men across the West Midlands and beyond. Services include maternity, gynecology, fetal medicine, neonatal intensive care, genetics, radiology, specialist pathology and fertility medicine. WMRGL provides fully comprehensive germline and cancer genetic diagnostic programme services with a strong research and development component to a population of nearly 6 million and is the largest NHS diagnostic laboratory in the UK.